EyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
January 31 2024 - 7:00AM
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed
to developing and commercializing therapeutics to improve the lives
of patients with serious retinal diseases, today announced that
George Elston, Executive Vice President and Chief Financial Officer
of EyePoint Pharmaceuticals, will participate in a fireside chat at
the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
on Wednesday, February 7, 2024 at 12:30 p.m. ET.
A live webcast and subsequent archived replay of
the fireside chat may be accessed via the Investors section of the
Company website at www.eyepointpharma.com. The replay will be
available for 90 days after the event.
About EyePoint
Pharmaceuticals
EyePoint Pharmaceuticals (Nasdaq: EYPT) is a
clinical-stage biopharmaceutical company committed to developing
and commercializing therapeutics to help improve the lives of
patients with serious retinal diseases. The Company's pipeline
leverages its proprietary bioerodible Durasert E™ technology for
sustained intraocular drug delivery. The Company’s lead product
candidate, EYP-1901, is an investigational sustained delivery
treatment for VEGF-mediated retinal diseases combining vorolanib, a
selective and patent-protected tyrosine kinase inhibitor with
Durasert E™. Additional pipeline programs include EYP-2301, a
promising TIE-2 agonist, razuprotafib, f/k/a AKB-9778, formulated
in Durasert E™ to potentially improve outcomes in serious retinal
diseases. The proven Durasert® drug delivery technology has been
safely administered to thousands of patient eyes across four U.S.
FDA approved products. EyePoint Pharmaceuticals is headquartered in
Watertown, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by
Equinox Sciences for the localized treatment of all ophthalmic
diseases outside of China, Macao, Hong Kong and Taiwan.
Investors:Christina
TartagliaStern IRDirect:
212-698-8700christina.tartaglia@sternir.com
Media ContactAmy PhillipsGreen
Room CommunicationsDirect:
412-327-9499aphillips@greenroompr.com
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
From Apr 2023 to Apr 2024
